Drugs / ONCT-534
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05917470 | Sep 2023 → Sep 2024 | castration-resistant prostate carcinoma | Oncternal Therapeutics, Inc | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONCT-534 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05917470 ↗ |
| Action | Inhibit | “inhibition of AR function and degradation of the AR protein” NCT05917470 ↗ |
| Route | Oral | “to be administered daily in oral tablets” NCT05917470 ↗ |
| Target | AR | “inhibition of AR function” NCT05917470 ↗ |